

# **IVIEW Collaboration With Dr. Amin Javer at St. Paul's Hospital and Sinus Centre, Canada to Study Povidone Iodine Formulations Including IVIEW-1503, a Long-Lasting Povidone Iodine Nasal Spray for the Treatment of COVID-19**

**PRESS RELEASE UPDATED: SEP 17, 2020 14:00 EDT**

**DOYLESTOWN, Pa., September 17, 2020 (NewsWire.com)** - IVIEW Therapeutics Inc., an innovative clinical-stage specialty pharmaceutical company, is proud to announce that Health Canada has offered Dr. Amin Javer, a renowned rhinologist at the St. Paul's Sinus Centre, University of British Columbia, Canada, a notification of Authorization for Clinical Trial Application of povidone iodine (PVP-I) formulations, including IVIEW's long-lasting PVP-I Nasal Spray: IVIEW-1503, for the treatment of COVID-19 patients.

Given the current state of the COVID pandemic, there is a large unmet need for treatments that could decrease infectivity or decrease the progression and morbidity of an infection with COVID-19. To that end, we have developed a gel-forming nasal solution with a known antiseptic (Povidone-Iodine), intended to decrease viral load in the nasopharynx and potentially improve the clinical course of COVID-19. IVIEW has collaborated with Dr. Amin Javer since early 2020 for the development of this innovative product for clinical evaluation. IVIEW's novel PVP-I formulation, IVIEW-1503, has shown promising results of completely eradicating SARS-CoV-2 virus to non-detectable levels within two minutes against the SARS-CoV-2 virus in an in-vitro virucidal assay.

In this proposed clinical study, we primarily aim to determine if topical PVP-I sinus rinses and throat gargles or a PVP-I gel-forming nasal spray will result in a reduction in the duration of a positive saliva test and in the SARS-CoV-2 viral load compared to a control placebo group. The gel-forming nasal spray is designed to stay in the nasal cavity for a prolonged period of time and to therefore determine if the length of contact of the Iodine within the sinonasal cavity will have a superior outcome. Dr. Javer commented, "This treatment could be a potential gamechanger by potentially being able to reduce the viral load and ultimately the illness itself to tolerable levels for those who have become exposed to the coronavirus."

Dr. Bo Liang, Chairman & President of IVIEW Therapeutics, commented, “The development of a dilute PVP-I nasal formulation would be a great asset in fighting the COVID-19 pandemic by treating and preventing further progression of the debilitating infection that may lead to dangerous symptoms.”

**About IVIEW Therapeutics Inc.**

IView Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of ophthalmology therapeutics. IVIEW Therapeutics is headquartered in Pennsylvania Biotechnology Center of Bucks County. For additional information on IView, please visit the Company’s website at [www.iviewtherapeutics.com](http://www.iviewtherapeutics.com).

**About St. Paul’s Sinus Centre, University of British Columbia**

St. Paul’s Sinus Centre is a tertiary and quaternary center of excellence for the medical and surgical management of the most difficult sinus and skull base diseases. It has a robust research team that carries out advanced translational research for diseases of the sinuses and the upper and lower airways, cystic fibrosis, HHT and other sinonasal related illnesses. <https://www.stpaulssinuscentre.com>

Source: IVIEW Therapeutics Inc.